구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab vedotin (recombinant) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | CD30 |
Overview Indication | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin combined with the ifosfamide and gemcit |
Technology Linker | non-cleavable linker, and a unique payload |
MoA Mechanism | targets the tissue factor pathway |
MoA Biomarker | biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Safety signal | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Selected reported efficacy | ORR 22% |
Clinical Reported ORR | 22% |
Clinical Result source | ClinicalTrials.gov NCT00894803 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00894803 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab vedotin (recombinant) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | CD30 |
Overview Indication | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin combined with the ifosfamide and gemcit |
Technology Linker | non-cleavable linker, and a unique payload |
MoA Mechanism | targets the tissue factor pathway |
MoA Biomarker | biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Safety signal | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Selected reported efficacy | ORR 22% |
Clinical Reported ORR | 22% |
Clinical Result source | ClinicalTrials.gov NCT00894803 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00894803 |
추천 비교
추천 비교